Why Trulieve Cannabis Stock Is Back In Focus After Its NYSE Debut

Trulieve Cannabis (TRLV) drew fresh attention after ringing the New York Stock Exchange Closing Bell and becoming the first U.S. cannabis company to list on the NYSE. The move signals higher visibility and potentially wider investor access.

The NYSE listing sits alongside Trulieve Cannabis operations that include 207 medical dispensaries, 5,000 employees, and 3.5 million square feet of cultivation and production capacity across several U.S. states. For investors, this combination of scale and a major exchange listing sets the backdrop for reassessing the stock.

Trulieve Cannabis has seen momentum build around its NYSE debut, with the share price at $9.69 and a 30-day share price return of 10.24%, while the 1-year total shareholder return of 35.34% contrasts with a 5-year total shareholder return that declined 64.57%.

If this kind of sector milestone has your attention, it can be a useful moment to broaden your watchlist with other growth stories using the 21 top founder-led companies

After Trulieve Cannabis stock rallied around its NYSE debut, the key issue now is simple. Has the recent move already reflected most of the good news, or does the current valuation still leave room for further upside potential?

Most Popular Narrative: 46.7% Undervalued

With Trulieve Cannabis last closing at $9.69 and the most followed narrative pointing to a fair value of $18.18 using a 7.24% discount rate, the gap between price and narrative value is wide enough to warrant a closer look at what is driving that view.

A strong cash position of US$353 million against US$290 million in debt and positive free cash flow of US$42 million in the quarter provide room to fund new stores, production upgrades and possible acquisitions, which can influence future revenue and earnings power.

Want to see what sits behind that cash and free cash flow story? The narrative rests on shifting margins, changing revenue expectations and a future earnings multiple that is far from conservative.

Result: Fair Value of $18.18 (UNDERVALUED)

However, Trulieve Cannabis still faces meaningful uncertainties, including the timing and scope of US federal rescheduling benefits and ongoing pricing pressure that could affect future margins.

Next Steps

With both clear risks and potential rewards on the table for Trulieve Cannabis, it makes sense to move quickly and test the numbers yourself. To weigh both sides of the story and see how they balance out for your own portfolio, start by reviewing the 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Trulieve Cannabis?

If Trulieve Cannabis has sharpened your focus, do not stop there. Use the Simply Wall Street Screener to spot fresh opportunities that match your investing style.

• Target potential bargains by scanning companies that appear mispriced and supported by fundamentals through the 50 high quality undervalued stocks.
• Prioritise resilience by checking companies that show sturdier finances and healthier balance sheets using the solid balance sheet and fundamentals stocks screener (50 results).
• Hunt for overlooked opportunities by reviewing the screener containing 20 high quality undiscovered gems before the crowd pays attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.